To include your compound in the COVID-19 Resource Center, submit it here.

Matinas' MAT2203 meets in Phase IIa for mucocutaneous candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported data from three evaluable patients with chronic refractory mucocutaneous candidiasis in

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE